A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Solid Tumors
Latest Information Update: 24 Jul 2024
At a glance
- Drugs BL-M07D1 (Primary)
- Indications Biliary cancer; Carcinoma; Gastrointestinal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 06 Mar 2024 Status changed from not yet recruiting to recruiting.
- 30 Jan 2024 Planned End Date changed from 1 Nov 2025 to 1 Mar 2026.
- 30 Jan 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Mar 2026.